100% Original Products
Fast Delivery within 24-72 Hours
Cash On Delivery Available
24/7 Order Support via whatsapp
NSAID for inflammatory pain management
Inflammatory Pain Relief:
Osteoarthritis • Rheumatoid arthritis • Ankylosing spondylitis
Acute trauma • Lumbago • Dental pain
(Use under registered physician's guidance)
Potent COX-1/COX-2 inhibitor → suppresses prostaglandin synthesis
Key Effects:
Anti-inflammatory • Analgesic • Antipyretic
Absorption: Rapid and complete (oral bioavailability >99%)
Tₘₐₓ: 1.3-3 hours
Half-life: 4-4.3 hours
Metabolism: Hepatic (CYP2C9) → active metabolite *4'-hydroxyaceclofenac*
Excretion: Renal (70-80%)
| Formulation | Dosing Regimen | Max Daily |
|---|---|---|
| Extended-Release | 200 mg once daily | 200 mg |
| Film-Coated | 100 mg twice daily | 200 mg |
| Critical Notes: |
Take with food to reduce GI irritation
Use lowest effective dose for shortest duration
(Follow registered physician's advice)
| Concomitant Drug | Risk | Action |
|---|---|---|
| Anticoagulants | ↑ Bleeding risk (INR elevation) | Avoid combination |
| Lithium/Digoxin | ↑ Plasma levels → toxicity | Monitor levels; reduce dose |
| Diuretics | ↓ Efficacy → ↑ nephrotoxicity | Hydration + renal monitoring |
| Methotrexate | ↑ Myelotoxicity | Avoid or space dosing by 48h |
Hypersensitivity to NSAIDs/aspirin
History of NSAID-induced asthma/bronchospasm
Active GI bleeding/peptic ulcer
Third trimester pregnancy
Severe heart failure (NYHA Class IV)
Common (≥5%):
Dyspepsia • Nausea • Abdominal pain • Diarrhea
Dizziness • Headache
Serious (Require Discontinuation):
GI ulceration/hemorrhage (melena, hematemesis)
Hepatotoxicity (↑ ALT/AST >3× ULN)
Renal impairment (↑ creatinine, oliguria)
Cardiovascular thrombosis (MI/stroke)
Pregnancy (Category C):
Avoid in first/second trimester unless essential
Contraindicated in third trimester (premature ductus arteriosus closure)
Lactation:
Excreted in milk; avoid nursing
GI Risk:
Screen for H. pylori; add PPI in high-risk patients (age >65, steroid co-therapy)
Cardiovascular:
Avoid in established CAD/stroke; monitor BP
Hepatic/Renal:
Baseline and periodic LFTs/renal function
Avoid if CrCl <30 mL/min or Child-Pugh C
Hypersensitivity:
Cross-reactivity with sulfonamides/salicylates
| Group | Guidance |
|---|---|
| Elderly | ↑ GI/CV risk → start at 50% dose |
| Renal Impairment | Avoid if CrCl <30 mL/min |
| Hepatic Impairment | Avoid in severe cirrhosis (Child-Pugh C) |
| Pediatrics | Safety not established |
Non-Steroidal Anti-Inflammatory Drug (NSAID)
Below 30°C • Protect from light/moisture
Keep out of children's reach
Your email address will not be published. Required fields are marked *
Please login to write review!
Looks like there are no reviews yet.
Comment